Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025

Core Viewpoint - Acorda Therapeutics will regain global commercialization rights to FAMPYRA following Biogen's decision to terminate their collaboration agreement, effective January 1, 2025, allowing Acorda to enhance its market presence and provide access to the medication for multiple sclerosis patients worldwide [1][2]. Group 1: Company Overview - Acorda Therapeutics develops therapies aimed at restoring function and improving the lives of individuals with neurological disorders, including products like INBRIJA for Parkinson's disease and AMPYRA for multiple sclerosis [5]. Group 2: Product Information - FAMPYRA is a prolonged-release formulation of fampridine, indicated for improving walking in adults with multiple sclerosis who have walking disabilities, with the highest reported adverse reaction being urinary tract infections [3]. - AMPYRA is an extended-release formulation of dalfampridine, which acts as a potassium channel blocker to help improve walking speed in adults with multiple sclerosis [4]. Group 3: Transition Plan - Acorda and Biogen are collaborating on a transition plan for Acorda to take over the commercialization and supply of FAMPYRA for the majority of multiple sclerosis patients outside the U.S., with plans to assume responsibilities in 2024 as marketing authorizations and distribution arrangements are finalized [1].